Shelf-life extension program (SLEP) as a significant contributor to strategic national stockpile maintenance: The Israeli experience with ciprofloxacin

Moran Bodas, Landschaft Yuval, Ron Zadok, Zippora Hess, Batya Haran, Mimi Kaplan, Arik Eisenkraft

Research output: Contribution to journalReview articlepeer-review

Abstract

In the past decade, the 2001 anthrax incident in the U.S. and the 2003 SARS epidemic have highlighted the biological threat to civilian populations. The risk posed by the natural or manmade spread of biological agents among the population dictates a need for better national preparedness. One key component of this preparation is the establishment of a Strategic National Stockpile (SNS) of pharmaceuticals that would provide appropriate medical countermeasures in case of an outbreak. However, to reduce the expense of such a stockpile and to make it worthwhile, there is also a need for a shelf-life extension program (SLEP) through which pharmaceuticals could be extended beyond manufacturer-ascribed shelf life, as long as they meet regulation standards. In this article, we review the Israeli experience with the national ciprofloxacin stockpile procurement and shelf-life extension program.

Original languageEnglish
Pages (from-to)182-187
Number of pages6
JournalBiosecurity and Bioterrorism
Volume10
Issue number2
DOIs
StatePublished - 1 Jun 2012

Fingerprint

Dive into the research topics of 'Shelf-life extension program (SLEP) as a significant contributor to strategic national stockpile maintenance: The Israeli experience with ciprofloxacin'. Together they form a unique fingerprint.

Cite this